Search

Your search keyword '"Bründl J"' showing total 160 results
Start Over Author "Bründl J"
160 results on '"Bründl J"'

2. Flappen oder nicht flappen? Ein systematischer Review inkl. Meta-Analyse aller randomisiert-kontrollierten Studien zum Benefit eines Peritoneal-Interposition-Flaps auf das Outcome nach Roboter-assistierter radikaler Prostatektomie mit Lymphadenektomie

Author

Bründl, J, Gilfrich, C, Wolff, I, Thomas, C, Ubrig, B, Wagner, J, Student, V, Merseburger, A, Brookman-May, S, May, M, Bründl, J, Gilfrich, C, Wolff, I, Thomas, C, Ubrig, B, Wagner, J, Student, V, Merseburger, A, Brookman-May, S, and May, M

Published
2023

3. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum

Author

Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Claps, F., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, T.H. van der, Babjuk, M., Sylvester, R.J., Rhijn, B.W.G. van, Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Claps, F., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, T.H. van der, Babjuk, M., Sylvester, R.J., and Rhijn, B.W.G. van

Abstract

Contains fulltext : 294430.pdf (Publisher’s version ) (Open Access), BACKGROUND: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive. OBJECTIVE: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta-T1 bladder tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and time to progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox-regression models with interaction terms stratified by institution. RESULTS AND LIMITATIONS: Ta G3 represented 7.5% (387/5170) of Ta-T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 (p = 0.9) or T1 G3 (p = 0.4). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7-4.8%) of Ta G2, 13% (95% CI 9.3-17%) of Ta G3, and 20% (95% CI 17-23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 (p < 0.001) and longer than for T1 G3 (p = 0.002). Patients with Ta G3 NMIBC with concomitant carcinoma in situ (CIS) had worse prognosis and a similar time to progression as for patients with T1 G3 NMIBC with CIS (p = 0.5). Multivariable analyses for recurrence and progression showed similar results. CONCLUSIONS: The prognosis of Ta G3 tumors in terms of progression appears to be in between that of Ta G2 and T1 G3. However, patients with Ta G3 NMIBC with concomitant CIS have worse prognosis that is compar

Published
2023

4. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum

Author

Beijert, I.J., primary, Hentschel, A.E., additional, Bründl, J., additional, Compérat, E.M, additional, Plass, K., additional, Rodríguez, O., additional, Subiela Henríquez, J.D., additional, Hernández, V., additional, De La Peña, E., additional, Alemany, I., additional, Turturica, D., additional, Pisano, F., additional, Soria, F., additional, Čapoun, O., additional, Bauerová, L., additional, Pešl, M., additional, Bruins, H.M., additional, Runneboom, W., additional, Herdegen, S., additional, Breyer, J., additional, Brisuda, A., additional, Calatrava, A., additional, Rubio-Briones, J.., additional, Seles, M., additional, Mannweiler, S., additional, Bosschieter, J., additional, Kusuma, V.R.M., additional, Ashabere, D., additional, Huebner, N., additional, Cotte, J., additional, Mertens, L.S, additional, Masson-Lecomte, A., additional, Liedberg, F., additional, Cohen, D., additional, Lunelli, L., additional, Cussenot, O., additional, El Sheikh, S., additional, Volanis, D., additional, Côté, J., additional, Rouprêt, M., additional, Haitel, A., additional, Shariat, S.F., additional, Mostafid, A.H., additional, Nieuwenhuijzen, J.A., additional, Zigeuner, R., additional, Dominguez-Escrig, J.L., additional, Hacek, J., additional, Zlotta, A.R., additional, Burger, M., additional, Evert, M., additional, Hulsbergen - Van De Kaa, C.A., additional, Van Der Heijden, A.G., additional, Kiemeney, L.A.L.M., additional, Soukup, V., additional, Molinaro, L., additional, Gontero, P., additional, Llorente, C., additional, Algaba, F., additional, Palou, J., additional, N’Dow, J., additional, Ribal, M.J., additional, Van Der Kwast, T.H., additional, Babjuk, M., additional, Sylvester, R.J., additional, and Van Rhijn, B.W.G., additional

Published
2022
Full Text
View/download PDF

6. O3 - Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum

Author

Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M, Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., De La Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J.., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S, Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., El Sheikh, S., Volanis, D., Côté, J., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen - Van De Kaa, C.A., Van Der Heijden, A.G., Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N’Dow, J., Ribal, M.J., Van Der Kwast, T.H., Babjuk, M., Sylvester, R.J., and Van Rhijn, B.W.G.

Published
2022
Full Text
View/download PDF

9. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum

Author

Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Henríquez, J.D. Subiela, Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, Theodorus H. van der, Babjuk, M., Sylvester, R.J., Rhijn, B.W. van, Beijert, I.J., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Henríquez, J.D. Subiela, Hernández, V., Peña, E. de la, Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen-van de Kaa, C.A., Heijden, A.G. van der, Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N'Dow, J., Ribal, M.J., Kwast, Theodorus H. van der, Babjuk, M., Sylvester, R.J., and Rhijn, B.W. van

Abstract

Item does not contain fulltext, BACKGROUND: The pathological existence and clinical consequence of stage T1 grade 1 (T1G1) bladder cancer are the subject of debate. Even though the diagnosis of T1G1 is controversial, several reports have consistently found a prevalence of 2-6% G1 in their T1 series. However, it remains unclear if T1G1 carcinomas have added value as a separate category to predict prognosis within the non-muscle-invasive bladder cancer (NMIBC) spectrum. OBJECTIVE: To evaluate the prognostic value of T1G1 carcinomas compared to TaG1 and T1G2 carcinomas within the NMIBC spectrum. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta and T1 bladder tumors from 17 hospitals in Europe and Canada were analyzed. Transurethral resection (TUR) was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox regression models stratified by institution. RESULTS AND LIMITATIONS: T1G1 represented 1.9% (99/5170) of all carcinomas and 5.3% (99/1859) of T1 carcinomas. According to primary TUR dates, the proportion of T1G1 varied between 0.9% and 3.5% per year, with similar percentages in the early and later calendar years. We found no difference in time to recurrence between T1G1 and TaG1 (p = 0.91) or between T1G1 and T1G2 (p = 0.30). Time to progression significantly differed between TaG1 and T1G1 (p < 0.001) but not between T1G1 and T1G2 (p = 0.30). Multivariable analyses for recurrence and progression showed similar results. CONCLUSIONS: The relative prevalence of T1G1 diagnosis was low and remained constant over the past three decades. Time to recurrence of T1G1 NMIBC was comparable to that for other stage/grade NMIBC combinations. Time to progression of T1G1 NMIBC was comparable to that for T1G2 but not for TaG1, suggesting that treatment and surveillance of T1G1 carcinomas should be more like the approaches for T1G2 NMIBC in

Published
2022

13. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study

Author

Rhijn, B.W. van, Hentschel, A.E., Bründl, J., Compérat, E.M., Hernández, V., Čapoun, O., Bruins, H.M., Cohen, D., Rouprêt, M., Shariat, S.F., Mostafid, A.H., Zigeuner, R., Dominguez-Escrig, J.L., Burger, M., Soukup, V., Gontero, P., Palou, J., Kwast, Theodorus H. van der, Heijden, A.G. van der, Kiemeney, L.A., Babjuk, M., Sylvester, R.J., Rhijn, B.W. van, Hentschel, A.E., Bründl, J., Compérat, E.M., Hernández, V., Čapoun, O., Bruins, H.M., Cohen, D., Rouprêt, M., Shariat, S.F., Mostafid, A.H., Zigeuner, R., Dominguez-Escrig, J.L., Burger, M., Soukup, V., Gontero, P., Palou, J., Kwast, Theodorus H. van der, Heijden, A.G. van der, Kiemeney, L.A., Babjuk, M., and Sylvester, R.J.

Abstract

Item does not contain fulltext, BACKGROUND: In the current European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guideline, two classification systems for grade are advocated: WHO1973 and WHO2004/2016. OBJECTIVE: To compare the prognostic value of these WHO systems. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5145 primary Ta/T1 NMIBC patients from 17 centers were collected between 1990 and 2019. The median follow-up was 3.9 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariate and multivariable analyses of WHO1973 and WHO2004/2016 stratified by center were performed for time to recurrence, progression (primary endpoint), cystectomy, and duration of survival, taking into account age, concomitant carcinoma in situ, gender, multiplicity, tumor size, initial treatment, and tumor stage. Harrell's concordance (C-index) was used for prognostic accuracy of classification systems. RESULTS AND LIMITATIONS: The median age was 68 yr; 3292 (64%) patients had Ta tumors. Neither classification system was prognostic for recurrence. For a four-tier combination of both WHO systems, progression at 5-yr follow-up was 1.4% in low-grade (LG)/G1, 3.8% in LG/G2, 7.7% in high grade (HG)/G2, and 18.8% in HG/G3 (log-rank, p < 0.001). In multivariable analyses with WHO1973 and WHO2004/2016 as independent variables, WHO1973 was a significant prognosticator of progression (p < 0.001), whereas WHO2004/2016 was not anymore (p = 0.067). C-indices for WHO1973, WHO2004, and the WHO systems combined for progression were 0.71, 0.67, and 0.73, respectively. Prognostic analyses for cystectomy and survival showed results similar to those for progression. CONCLUSIONS: In this large prognostic factor study, both classification systems were prognostic for progression but not for recurrence. For progression, the prognostic value of WHO1973 was higher than that of WHO 2004/2016. The four-tier combination (LG/G1, LG/G2, HG/G2, and HG/G3) of both WHO systems proved to be superior, as it d

Published
2021

14. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

Author

Sylvester, R.J., Rodríguez, O., Hernández, V., Turturica, D., Bauerová, L., Bruins, H.M., Bründl, J., Kwast, Theodorus H. van der, Brisuda, A., Rubio-Briones, J., Seles, M., Hentschel, A.E., Kusuma, V.R.M., Huebner, N., Cotte, J., Mertens, L.S., Volanis, D., Cussenot, O., Henríquez, J.D. Subiela, Peña, E. de la, Pisano, F., Pešl, M., Heijden, A.G. van der, Herdegen, S., Zlotta, A.R., Hacek, J., Calatrava, A., Mannweiler, S., Bosschieter, J., Ashabere, D., Haitel, A., Côté, J.F., Sheikh, S., Lunelli, L., Algaba, F., Alemany, I., Soria, F., Runneboom, W., Breyer, J., Nieuwenhuijzen, J.A., Llorente, C., Molinaro, L., Hulsbergen-van de Kaa, C.A., Evert, M., Kiemeney, L.A., N'Dow, J., Plass, K., Čapoun, O., Soukup, V., Dominguez-Escrig, J.L., Cohen, D., Palou, J., Gontero, P., Burger, M., Zigeuner, R., Mostafid, A.H., Shariat, S.F., Rouprêt, M., Compérat, E.M., Babjuk, M., Rhijn, B.W. van, Sylvester, R.J., Rodríguez, O., Hernández, V., Turturica, D., Bauerová, L., Bruins, H.M., Bründl, J., Kwast, Theodorus H. van der, Brisuda, A., Rubio-Briones, J., Seles, M., Hentschel, A.E., Kusuma, V.R.M., Huebner, N., Cotte, J., Mertens, L.S., Volanis, D., Cussenot, O., Henríquez, J.D. Subiela, Peña, E. de la, Pisano, F., Pešl, M., Heijden, A.G. van der, Herdegen, S., Zlotta, A.R., Hacek, J., Calatrava, A., Mannweiler, S., Bosschieter, J., Ashabere, D., Haitel, A., Côté, J.F., Sheikh, S., Lunelli, L., Algaba, F., Alemany, I., Soria, F., Runneboom, W., Breyer, J., Nieuwenhuijzen, J.A., Llorente, C., Molinaro, L., Hulsbergen-van de Kaa, C.A., Evert, M., Kiemeney, L.A., N'Dow, J., Plass, K., Čapoun, O., Soukup, V., Dominguez-Escrig, J.L., Cohen, D., Palou, J., Gontero, P., Burger, M., Zigeuner, R., Mostafid, A.H., Shariat, S.F., Rouprêt, M., Compérat, E.M., Babjuk, M., and Rhijn, B.W. van

Abstract

Item does not contain fulltext, BACKGROUND: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. OBJECTIVE: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel. INTERVENTION: Patients underwent TURBT followed by intravesical instillations at the physician's discretion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves. RESULTS AND LIMITATIONS: A total of 3401 patients treated with TURBT ± intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review. CONCLUSIONS: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for wh

Published
2021

16. Wirksamkeit des Peritonealpatchs in der Reduktion postoperativer Lymphozelen nach pelviner Lymphadenektomie im Rahmen der roboter-assistierten radikalen Prostatektomie – Ergebnisse einer multizentrischen randomisiert-kontrollierten Studie

Author

May, M, Gilfrich, C, Stojanoski, G, Ponholzer, A, Weikert, S, Burger, M, Lenart, S, and Bründl, J

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund: Lymphozelen stellen die häufigste Komplikation nach pelviner Lymphadenektomie (PLA) im Rahmen der roboter-assistierten radikalen Prostatektomie (RARP) dar. In einer retrospektiven Studie konnte der präventive Stellenwert eines Peritonealpatches hinsichtlich der Lymphozelenrate[zum vollständigen Text gelangen Sie über die oben angegebene URL], 46. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Published
2020
Full Text
View/download PDF

19. P119 - Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?

Author

Hentschel, A.E., Van Rhijn, B.W.G., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., De La Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Čapoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Scavarda-Lamberti, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Cotte, J., Mertens, L.S., Cohen, D., Lunelli, L., Cussenot, O., El Sheikh, S., Volanis, D., Coté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Dominguez-Escrig, J.L., Hacek, J., Zlotta, A.R., Burger, M., Evert, M., Hulsbergen - Van De Kaa, C.A., Van Der Heijden, A.G., Kiemeney, L.A.L.M., Soukup, V., Molinaro, L., Gontero, P., Llorente, C., Algaba, F., Palou, J., N’dow, J., Babjuk, M., Van Der Kwast, T.H., and Sylvester, R.J.

Published
2019
Full Text
View/download PDF

20. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?

Author

Hentschel, A.E., primary, Van Rhijn, B.W.G., additional, Bründl, J., additional, Compérat, E.M., additional, Plass, K., additional, Rodríguez, O., additional, Subiela Henríquez, J.D., additional, Hernández, V., additional, De La Peña, E., additional, Alemany, I., additional, Turturica, D., additional, Pisano, F., additional, Soria, F., additional, Čapoun, O., additional, Bauerová, L., additional, Pešl, M., additional, Bruins, H.M., additional, Runneboom, W., additional, Herdegen, S., additional, Breyer, J., additional, Brisuda, A., additional, Scavarda-Lamberti, A., additional, Calatrava, A., additional, Rubio-Briones, J., additional, Seles, M., additional, Mannweiler, S., additional, Bosschieter, J., additional, Kusuma, V.R.M., additional, Ashabere, D., additional, Huebner, N., additional, Cotte, J., additional, Mertens, L.S., additional, Cohen, D., additional, Lunelli, L., additional, Cussenot, O., additional, El Sheikh, S., additional, Volanis, D., additional, Coté, J.F., additional, Rouprêt, M., additional, Haitel, A., additional, Shariat, S.F., additional, Mostafid, A.H., additional, Nieuwenhuijzen, J.A., additional, Zigeuner, R., additional, Dominguez-Escrig, J.L., additional, Hacek, J., additional, Zlotta, A.R., additional, Burger, M., additional, Evert, M., additional, Hulsbergen - Van De Kaa, C.A., additional, Van Der Heijden, A.G., additional, Kiemeney, L.A.L.M., additional, Soukup, V., additional, Molinaro, L., additional, Gontero, P., additional, Llorente, C., additional, Algaba, F., additional, Palou, J., additional, N’dow, J., additional, Babjuk, M., additional, Van Der Kwast, T.H., additional, and Sylvester, R.J., additional

Published
2019
Full Text
View/download PDF

25. Ki67-Überexpression ist ein unabhängiger Prädiktor für das Rezidiv beim pTa Urothelkarzinom der Harnblase

Author

Breyer, J., Shalekenov, S., Aziz, A., van Rhijn, B.W.G., Bründl, J., Lausenmeyer, E.M., Schäfer, J., Denzinger, S., Giedl, C., Burger, M., Hartmann, A., Evert, M., and Otto, W.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Für das Urothelkarzinom im Stadium pT1 oder für das muskelinvasive Urothelkarzinom konnte bereits in mehreren Untersuchungen ein Zusammenhang zwischen einer Überexpression des Proliferationsmarkers Ki67 und einem schlechteren Outcome nachgewiesen werden. Ziel der vorliegenden[zum vollständigen Text gelangen Sie über die oben angegebene URL], 43. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung

Published
2017

26. Urologische Oberärztinnen und Oberärzte an universitären oder nicht-universitären Kliniken – welche Unterschiede gibt es? : Ergebnisse einer webbasierten Querschnittstudie an deutschen Kliniken.

Author

May, M., Wolff, I., Bründl, J., Kriegmair, M. C., Marghawal, D., Wülfing, C, Burger, M., Necknig, U., Schäfer, C., and DGU-Arbeitsgruppe „Urologische Oberärztinnen und Oberärzte“

Abstract

Copyright of Der Urologe A is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

27. Forschungsvoraussetzungen, -skills und -leistungen urologischer Nachwuchswissenschaftler in Deutschland.

Author

Borgmann, H., Bründl, J., Huber, J., Ruf, C., Schagdarsurgengin, U., Wullich, B., Salem, J., and Bründl, J

Abstract

Copyright of Der Urologe A is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

30. Facharztweiterbildung in der Niederlassung – Im Spannungsfeld zwischen Rahmenbedingungen, Bereitschaft und Wirklichkeit

Author

Lausenmeyer, EM, Borgmann, H, Bründl, J, Salem, J, Schroeder, A, and Heidenreich, A

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Die niedergelassenen Urologen werden älter und der Nachwuchs fehlt. Ambulante Behandlungen und Operationen werden mehr. Durch den demographischen Wandel steigen die Patientenzahlen. Das Behandlungsspektrum in der Klinik wandelt sich und Weiterbildungsassistenten fehlt dadurch die[zum vollständigen Text gelangen Sie über die oben angegebene URL], 42. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Published
2016
Full Text
View/download PDF

31. Tripple trouble: Erstbeschreibung eines synchronen Dreifach-Urothelkarzinoms der Harnblase und beider Harnleiter

Author

Otto, W, Berger, S, Bründl, J, Gierth, M, Eichelberg, C, Fritsche, HM, Denzinger, S, Burger, M, and Breyer, J

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Harnleitertumoren machen nur etwa 5% aller Urothelkarzinome aus, synchrones Vorkommen von beidseitigen Harnleiterkarzinomen stellt eine Rarität dar. Die gleichzeitige Diagnose von beidseitigen Uretertumoren und eines Harnblasenkarzinoms wurde noch nie beschrieben. Fallbeschreibung:[zum vollständigen Text gelangen Sie über die oben angegebene URL], 42. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Published
2016
Full Text
View/download PDF

32. Anatomische Studie der erektilen Nerven im Verlauf von Samenblasen, Prostata und Harnröhrenschließmuskel - was ist relevant für die nervschonende radikale Prostatektomie?

Author

Ganzer, R., Stolzenburg, J.-U., Neuhaus, J., Weber, F., Fuchshofer, R., Burger, M., and Bründl, J.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Anatomische Studien zum Verlauf der erektilen Nerven sind wichtig für die Optimierung funktioneller Ergebnisse nach radikaler Prostatektomie. Der Großteil aktueller Untersuchungen beschreibt jedoch ausschließlich die Anatomie periprostatischer Nerven. Mit unserer Untersuchung[for full text, please go to the a.m. URL], 41. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung

Published
2015

33. Solides Tumorwachstum, symptomlose Diagnosestellung und verzögerte Zystektomie sind die bedeutendsten klinisch erhebbaren Parameter zur Prognoseabschätzung des tumorspezifischen Überlebens von pT1-Harnblasenkarzinomen

Author

Breyer, J., Lausenmeyer, E.M., Bumes, B., Herdegen, S., Burger, M., Bründl, J., Gierth, M., Denzinger, S., and Otto, W.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Das Urothelkarzinom der Harnblase (UBC) im Stadium pT1 ist eine Erkrankung mit heterogenem klinischem Verlauf. Die richtige Therapiestrategie für den einzelnen Patienten zu wählen, bleibt eine Herausforderung. Zielsetzung der vorliegenden Studie war es, klinische Einflussfaktoren[for full text, please go to the a.m. URL], 41. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung

Published
2015

36. Regional for Residents

Author

Paffenholz, P., primary, Borgmann, H., additional, Nachite-Berges, S., additional, Borowitz, R., additional, Bründl, J., additional, Boehm, K., additional, Probst, K., additional, Schneidewind, L., additional, Schmid, M., additional, and Salem, J., additional

Published
2016
Full Text
View/download PDF

39. Kombination von Elastographie-gesteuerter und Randombiopsie der Prostata - Vergleich zweier Kombinationsschemata

Author

Schnabel, M.J., Gierth, M., Bründl, J., Brandtner, A., Fritsche, H.-M., Wieland, W.F., and Ganzer, R.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Den Goldstandard der histologischen Abklärung des Prostatakarzinoms stellt die 10- bis 12-fach randomisierte Prostatastanzbiopsie dar. Durch den Einsatz der Elastographie-gesteuerten Prostatastanzbiopsie ist eine Steigerung der Detektionsrate durch die gezielte Biopsie suspekter [for full text, please go to the a.m. URL], 39. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie sowie der Bayerischen Urologenvereinigung

Published
2013
Full Text
View/download PDF

40. Stellenwert der HIFU Therapie bei der Behandlung des lokal begrenzten Prostatakarzinoms - Langzeitdaten von 538 Patienten im Zeitraum von 14 Jahren

Author

Ganzer, R., Fritsche, H.-M., Brandtner, A., Bründl, J., Koch, D., Wieland, W.F., and Blana, A.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Der Einsatz der HIFU-Therapie bei der Behandlung des lokal begrenzten Prostatakarzinom (PC) wird innerhalb der Europäischen Fachgesellschaften unterschiedlich bewertet. Ein Grund hierfür sind fehlende Langzeitdaten. Ziel unserer Studie war die Erhebung des kompletten Follow-up [for full text, please go to the a.m. URL], 39. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie sowie der Bayerischen Urologenvereinigung

Published
2013

41. Quantifizierung und Planimetrie von prostatischen Kapselnerven in Abhängigkeit benachbarter Tumorfoci

Author

Ganzer, R., Schneider, S., Weber, F., Zeman, F., Wieland, W.F., and Bründl, J.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Perineuralscheideninfiltration (PNI) gilt als wichtiger Mechanismus bei der Metastasierung des Prostatakarzinoms (PC). Nachdem die PNI zunächst als low-resistance Mechanismus verstanden wurde, konnten neuere in-vitro Untersuchungen eine komplexe Neuro-epitheliale Interaktion als[for full text, please go to the a.m. URL], 39. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie sowie der Bayerischen Urologenvereinigung

Published
2013
Full Text
View/download PDF

42. Anamnese, pathologische Originalbefunde, Therapie bezogene Parameter und Krankheitsverlauf: retrospektive Analyse von klinisch basierten Faktoren für die Prognose des tumorspezifischen Überlebens von 378 Patienten mit pT1-Harnblasenkarzinom

Author

Breyer, J., additional, Otto, W., additional, Hartmann, A., additional, Bumes, B., additional, Bründl, J., additional, Gierth, M., additional, Bertz, S., additional, Denzinger, S., additional, Burger, M., additional, and Lausenmeyer, E., additional

Published
2015
Full Text
View/download PDF

44. Urethrale Condylomata acuminata

Author

Brummeisl, W., primary, Lausenmeyer, E., additional, Weber, F., additional, Bründl, J., additional, Fritsche, H.-M., additional, Burger, M., additional, and Denzinger, S., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results